New Tricks by an Old Dog

Forst, Thomas; Wahren, John
January 2009
Experimental Diabetes Research;2009, Special section p1
Academic Journal
An introduction to articles published within the issue is presented, including an authoritative review of the history and diagnostic aspects of C-peptide, an update on C-peptide physiology and the role of C-peptide deficiency in the development of microvascular complications of type 1 diabetes.


Related Articles

  • The Effects of C-peptide on Type 1 Diabetic Polyneuropathies and Encephalopathy in the BB/Wor-rat. Sima, Anders A. F.; Weixian Zhang; Zhen-guo Li; Kamiya, Hideki // Experimental Diabetes Research;2008, p1 

    Diabetic polyneuropathy (DPN) occurs more frequently in type 1 diabetes resulting in a more severe DPN. The differences in DPN between the two types of diabetes are due to differences in the availability of insulin and C-peptide. Insulin and C-peptide provide gene regulatory effects on...

  • Effect of C-Peptide on Diabetic Neuropathy in Patients with Type 1 Diabetes. Ekberg, Karin; Johansson, Bo-Lennart // Experimental Diabetes Research;2008, Special section p1 

    Recent results indicate that proinsulin C-peptide, contrary to previous views, exerts important physiological effects and shows the characteristics of a bioactive peptide. Studies in type 1 diabetes, involving animal models as well as patients, demonstrate that C-peptide in replacement doses has...

  • Fulminant Type 1 Diabetes as a Model of Nature to Explore the Role of C-Peptide. Murase-Mishiba, Yuko; Imagawa, A.; Hanafusa, Toshiaki // Experimental Diabetes Research;2009, Special section p1 

    Patients with fulminant type 1 diabetes almost completely lack C-peptide even soon after the onset of the disease, and the deficiency continues for the rest of their life. Thus, fulminant type 1 diabetes could serve as a good model of nature to explore the physiological role of C-peptide. For...

  • A Case of Fulminant Type 1 Diabetes Mellitus with Human Leukocyte Antigen DR4-DQ4. Ye-Ri So; Ja-Won Koo; Young-Hak Cho; You-Cheol Hwang; Kyu-Jeung Ahn; Ho-Yeon Chung; In-Kyung Jeong // Endocrinology & Metabolism;Dec2012, Vol. 27 Issue 4, p314 

    The clinical characteristics of fulminant type 1 diabetes are abrupt onset of disease, very short (<1 week) duration of diabetic symptoms, ketoacidosis at diagnosis, negativity for islet-related autoantibodies, virtually no C-peptide secretion (fasting plasma C-peptide <0.3 ng/mL), a near normal...

  • Type 1 Long-Termers Show 'Residual Islet Function.'.  // Diabetes Health;Sep2006, Vol. 15 Issue 9, p29 

    The article focuses on the presence of residual islet functioning in type 1 diabetics according to the Medalist Study by the Joslin Diabetes Center. The study has found out some islet function in type 1 diabetics. Evidence include C-peptide secretion and the presence of antibodies. The study...

  • Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial. Lachin, John M.; McGee, Paula; Palmer, Jerry P. // Diabetes;Feb2014, Vol. 63 Issue 2, p739 

    The Diabetes Control and Complications Trial established that a stimulated C-peptide concentration ›0.2 nmol/L at study entry among subjects with up to a 5-year diabetes duration is associated with favorable metabolic and clinical outcomes over the subsequent 7 years of follow-up. Herein...

  • Complications of Diabetes: General.  // Current Medical Literature: Diabetes;2003, Vol. 20 Issue 3, p79 

    Presents a number of citations and clinician's notes with regards to the complications of diabetes in general. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial; C-peptide responses; Shorter duration of diabetes in subjects...

  • Does partial preservation of residual beta-cell function justify immune intervention in recent onset Type I diabetes? Kolb, H.; Gale, E. A. M. // Diabetologia;Oct2001, Vol. 44 Issue 10, p1349 

    Immune intervention seems to offer the prospect of preventing or reversing the hyperglycaemic phase of Type I (insulin-dependent) diabetes mellitus. A number of prevention trials have been undertaken before disease onset but the logistics of such trials are prohibitive. More rapid and less...

  • The Clinical Potential of C-Peptide Replacement in Type 1 Diabetes. Wahren, John; Kallas, Åksa; Sima, Anders A. F. // Diabetes;Apr2012, Vol. 61 Issue 4, p761 

    The article focuses on a study which examined the physiology of C-peptide and its potential role in the treatment of type 1 diabetes complications. Topics discussed include the application of physiological concentrations of C-peptide to renal tubular cells and endothelial cells which results in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics